FIELD: medicine.
SUBSTANCE: invention can be used to determine the optimal monoendocellular cryopreserving agent for a particular patient for cells storage at -80°C. The method is characterized by comparative study of the zonal structures of dried supernatant droplets with various cryopreserving agents frozen to minus 80°C, as well as before and after certain time intervals after the test in the in vitro transfusion model. When the structure of the central, middle and marginal zones of control and experimental microbiopreparations is similar, the cryopreserving agent applied is evaluated as optimal for the particular patient.
EFFECT: method allows individual screening of the cryopreserving agent at the early preclinical stage of manifestation of critical homeostasis disorder of a cryoprotective agent.
1 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR IDENTIFYING AN EFFECTIVE CRYOPROTECTOR BY CYTOCHEMICAL INDEX OF THE CONTENT OF LEUKOCYTE ALKALINE PHOSPHATASE OF AUTOLOGOUS BLOOD | 2018 |
|
RU2676674C1 |
| METHOD OF OPTIMAL CRYOPROTECTOR SELECTION HAVING GLYCOGEN CONTENT IN PRESERVED BLOOD LEUKOCYTES | 2018 |
|
RU2686107C1 |
| METHOD FOR EVALUATING HOMEOSTASIS STATE | 1996 |
|
RU2114432C1 |
| METHOD FOR DETERMINING AN OPTIMAL CRYOPROTECTOR ACCORDING TO A CYTOCHEMICAL INDICATOR OF CONTENT OF SUCCINATE DEHYDROGENASE IN BLOOD PLASMA LEUKOCYTES | 2017 |
|
RU2689328C1 |
| METHOD FOR DETERMINING A PERSONALIZED CRYOPROTECTOR BY LEUKOCYTE ACID PHOSPHATASE OF PRESERVED BLOOD | 2017 |
|
RU2689334C1 |
| METHOD FOR DIAGNOSTICS OF ENDOGENOUS INTOXICATION OF CRYOPROTECTIVE GENESIS | 2016 |
|
RU2642270C1 |
| METHOD OF PREVENTION OF BLEEDING CAUSED BY THE APPLICATION OF ANTIAGREGANTS, EXPERIMENT STAGE | 2017 |
|
RU2645630C1 |
| METHOD FOR WASHING CRYOPRESERVED-THAWED PLATELETS FROM THE ENCLOSING SOLUTION | 2022 |
|
RU2795058C1 |
| METHOD FOR PREVENTING BLEEDING CAUSED BY USE OF WARFARIN IN EXPERIMENT | 2016 |
|
RU2645414C1 |
| WHOLE BLOOD CRYOPROTECTANT | 2023 |
|
RU2816446C1 |
